|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
DK3222722T3
(da)
*
|
2002-11-18 |
2019-06-17 |
Roche Innovation Ct Copenhagen As |
Antisense-design
|
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
|
DE102005042073B4
(de)
*
|
2005-08-31 |
2010-11-11 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Faserlaser
|
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
|
CN102908630B
(zh)
*
|
2006-01-27 |
2014-11-19 |
Isis制药公司 |
6-修饰的双环核酸类似物
|
|
EP2505650A1
(en)
*
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
|
AU2007257093A1
(en)
|
2006-05-05 |
2007-12-13 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PCSK9
|
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
EP2066684B1
(en)
*
|
2006-05-11 |
2012-07-18 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
EP2410054B2
(en)
|
2006-10-18 |
2019-12-11 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
EP2455471A3
(en)
*
|
2006-11-27 |
2012-09-12 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
CN103480002A
(zh)
|
2007-03-24 |
2014-01-01 |
基酶有限公司 |
施用与人载脂蛋白 b互补的反义寡核苷酸
|
|
DK2176280T4
(en)
†
|
2007-07-05 |
2015-07-20 |
Isis Pharmaceuticals Inc |
6-Disubstituerede bicykliske nukleinsyreanaloge
|
|
ES2439591T3
(es)
|
2007-08-15 |
2014-01-23 |
Isis Pharmaceuticals, Inc. |
Análogos de ácido nucleico de tetrahidropirano
|
|
CN101984759A
(zh)
|
2007-11-09 |
2011-03-09 |
Isis药物公司 |
因子9表达的调节
|
|
RU2010119775A
(ru)
|
2007-11-09 |
2011-12-27 |
Айсис Фармасьютикалс,Инк. (Us) |
Модулирование экспрессии фактора 7
|
|
EP2265627A2
(en)
*
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
US8426378B2
(en)
|
2008-03-21 |
2013-04-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucelosides and methods for their use
|
|
WO2009124238A1
(en)
*
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
US8541387B2
(en)
*
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Modulation of SMRT expression
|
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
|
WO2010019270A1
(en)
*
|
2008-08-14 |
2010-02-18 |
Isis Pharmaceuticals, Inc. |
Modulation of prion expression
|
|
KR101877698B1
(ko)
*
|
2008-08-25 |
2018-07-12 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
|
|
WO2010027832A1
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
US8946172B2
(en)
*
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
DK2361256T3
(da)
*
|
2008-09-24 |
2013-07-01 |
Isis Pharmaceuticals Inc |
Cyclohexenyl-nukleinsyreanaloger
|
|
WO2010036698A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
US8153606B2
(en)
|
2008-10-03 |
2012-04-10 |
Opko Curna, Llc |
Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
|
|
CA2966011C
(en)
|
2008-10-15 |
2021-10-19 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
EP2358398A2
(en)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
WO2010064146A2
(en)
|
2008-12-02 |
2010-06-10 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
RU2620970C2
(ru)
|
2008-12-04 |
2017-05-30 |
КьюРНА,Инк., |
Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
|
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
KR101761424B1
(ko)
|
2008-12-04 |
2017-07-26 |
큐알엔에이, 인크. |
Ｖｅｇｆ에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(ｖｅｇｆ) 관련된 질환의 치료
|
|
US9132147B2
(en)
|
2008-12-31 |
2015-09-15 |
Roche Innovation Center Copenhagen |
Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
|
|
WO2010090830A1
(en)
*
|
2009-01-20 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Modulation of sirt1 expression
|
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
|
WO2010090969A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
|
EP2396038B1
(en)
|
2009-02-12 |
2015-10-21 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
ES2656290T3
(es)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
|
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
WO2010120511A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Method of treating respiratory disorders
|
|
US20120046236A1
(en)
|
2009-05-06 |
2012-02-23 |
Opko Curna Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
|
WO2010129861A2
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
KR101749356B1
(ko)
|
2009-05-18 |
2017-07-06 |
큐알엔에이, 인크. |
재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료
|
|
EP2432882B1
(en)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
|
WO2010138806A2
(en)
|
2009-05-28 |
2010-12-02 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
|
MX2011013078A
(es)
|
2009-06-12 |
2012-02-01 |
Santaris Pharma As |
Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).
|
|
EP2443238B1
(en)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
|
CA2765700C
(en)
|
2009-06-16 |
2021-01-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
|
RU2566724C9
(ru)
|
2009-06-17 |
2019-03-12 |
Байоджен Ma Инк. |
Композиции и способы модуляции smn2 сплайсинга у субъекта
|
|
WO2010150789A1
(ja)
|
2009-06-23 |
2010-12-29 |
武田薬品工業株式会社 |
核酸の合成法
|
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
|
|
KR101807324B1
(ko)
|
2009-06-26 |
2017-12-08 |
큐알엔에이, 인크. |
다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
|
|
KR101885383B1
(ko)
|
2009-07-06 |
2018-08-03 |
웨이브 라이프 사이언시스 리미티드 |
신규한 핵산 프로드러그 및 그의 사용 방법
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
|
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
WO2011019815A2
(en)
|
2009-08-11 |
2011-02-17 |
Curna, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
EP2467482A4
(en)
|
2009-08-21 |
2013-12-11 |
Curna Inc |
TREATMENT OF DISEASES RELATED TO "CIP PROTEIN CHIP EXTREME (PROTEIN INTERACTING WITH HSP70)" BY INHIBITION OF CHIP NATURAL ANTISENSE TRANSCRIPT
|
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
JP5809146B2
(ja)
|
2009-09-11 |
2015-11-10 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
ハンチンチン発現の修飾
|
|
ES2664591T3
(es)
|
2009-09-25 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
|
|
EP2490699A1
(en)
|
2009-10-20 |
2012-08-29 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
|
WO2011079261A2
(en)
|
2009-12-23 |
2011-06-30 |
Curna, Inc. |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
|
CA2782375C
(en)
|
2009-12-23 |
2023-10-31 |
Opko Curna, Llc |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー，インコーポレイテッド |
核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
|
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
|
RU2616283C2
(ru)
|
2009-12-31 |
2017-04-13 |
Курна, Инк. |
Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2
|
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
|
CN106146591B
(zh)
|
2010-01-08 |
2020-07-31 |
Ionis制药公司 |
血管生成素样3表达的调节
|
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
RU2611191C2
(ru)
|
2010-01-11 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных со связывающим половые гормоны глобулином (гспг), путем ингибирования природного антисмыслового транскрипта к гспг
|
|
EP2524038A4
(en)
*
|
2010-01-12 |
2013-11-20 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION
|
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー，インコーポレイテッド |
ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
|
|
CA2789038A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP2534248B1
(en)
|
2010-02-08 |
2018-08-29 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
|
US20110213011A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Dean Nicholas M |
Modulation of smad3 expression
|
|
WO2011115817A1
(en)
|
2010-03-16 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
Methods of preparing 2'-o-substituted purine nucleosides
|
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
RU2612884C2
(ru)
|
2010-04-02 |
2017-03-13 |
Курна, Инк. |
Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
|
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
|
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
|
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
|
EP3091027B1
(en)
|
2010-04-28 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
NZ603339A
(en)
|
2010-04-29 |
2015-01-30 |
Isis Pharmaceuticals Inc |
Modulation of transthyretin expression
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
KR101992076B1
(ko)
|
2010-05-03 |
2019-06-21 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
EP3299464B1
(en)
|
2010-05-26 |
2019-10-02 |
CuRNA, Inc. |
Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
|
|
US8980858B2
(en)
|
2010-05-26 |
2015-03-17 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
|
|
WO2011153323A2
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR MODULATING THE INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
|
CN109112126B
(zh)
|
2010-06-23 |
2024-06-14 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
|
WO2012007477A1
(en)
|
2010-07-12 |
2012-01-19 |
Santaris Pharma A/S |
Anti hcv oligomers
|
|
NO2593547T3
(ja)
|
2010-07-14 |
2018-04-14 |
|
|
|
EP3031920B1
(en)
|
2010-07-19 |
2019-08-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (dmpk) expression
|
|
US9081737B2
(en)
|
2010-08-02 |
2015-07-14 |
Integrated Dna Technologies, Inc. |
Methods for predicting stability and melting temperatures of nucleic acid duplexes
|
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
CA2813901C
(en)
|
2010-10-06 |
2019-11-12 |
Curna, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
|
WO2012064758A2
(en)
|
2010-11-08 |
2012-05-18 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
|
CA3077910A1
(en)
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー，インコーポレイテッド |
Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
|
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
|
EP3067421B1
(en)
*
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
|
MX343008B
(es)
|
2011-03-29 |
2016-10-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
|
JP5943993B2
(ja)
|
2011-04-01 |
2016-07-05 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
転写のシグナル伝達及び活性化因子３（ｓｔａｔ３）発現の調節
|
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
|
KR102055331B1
(ko)
|
2011-04-21 |
2019-12-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
B형 간염 바이러스(hbv) 발현 조절
|
|
BR112013027187A2
(pt)
|
2011-04-25 |
2017-06-06 |
Regulus Therapeutics Inc |
composto que compreende um oligonucleotídeo modificado complementar a mir-21; oligonucleotídeo modificado; composição farmacêutica; método para diminuir a expressão de colágeno em uma célula; e uso de um composto
|
|
AU2012249324B2
(en)
|
2011-04-27 |
2016-10-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of apolipoprotein CIII (ApoCIII) expression
|
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9593330B2
(en)
|
2011-06-09 |
2017-03-14 |
Curna, Inc. |
Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
|
|
US9187749B2
(en)
|
2011-06-10 |
2015-11-17 |
Isis Pharmaceuticals, Inc. |
Methods for modulating factor 12 expression
|
|
AU2012267546B2
(en)
|
2011-06-10 |
2015-12-24 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
|
CA2839437A1
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
|
EP4092120A1
(en)
|
2011-06-21 |
2022-11-23 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (anglptl3) irna compositions and methods of use thereof
|
|
WO2012175733A1
(en)
|
2011-06-23 |
2012-12-27 |
Santaris Pharma A/S |
Hcv combination therapy
|
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
WO2013003808A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
|
WO2013000855A1
(en)
|
2011-06-30 |
2013-01-03 |
Santaris Pharma A/S |
Hcv combination therapy
|
|
KR20140058536A
(ko)
|
2011-06-30 |
2014-05-14 |
스텔라 에이피에스 |
Hcv 조합 치료
|
|
JP6128529B2
(ja)
|
2011-07-19 |
2017-05-17 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
官能化核酸の合成のための方法
|
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
EP3922722B1
(en)
|
2011-08-11 |
2023-06-28 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP3640332A1
(en)
|
2011-08-29 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
EP2753317B1
(en)
|
2011-09-06 |
2020-02-26 |
CuRNA, Inc. |
TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
|
|
DK2756080T3
(da)
|
2011-09-14 |
2019-05-20 |
Translate Bio Ma Inc |
Multimeriske oligonukleotidforbindelser
|
|
EP3401401B1
(en)
|
2011-09-20 |
2020-04-15 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of gcgr expression
|
|
IN2014CN03749A
(ja)
|
2011-10-25 |
2015-09-25 |
Isis Pharmaceuticals Inc |
|
|
EP2773777B1
(en)
|
2011-10-31 |
2020-05-13 |
University of Utah Research Foundation |
Genetic alterations in glioblastoma
|
|
ES2761343T3
(es)
|
2011-11-07 |
2020-05-19 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de TMPRSS6
|
|
WO2013068347A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
|
|
WO2013068348A1
(en)
|
2011-11-07 |
2013-05-16 |
Santaris Pharma A/S |
Lna oligomers for improvement in hepatic function
|
|
BR112014011018A2
(pt)
|
2011-11-11 |
2017-05-02 |
Santaris Pharma As |
compostos para modulação de splining de smn2
|
|
US9243291B1
(en)
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン，インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
|
EP2794880B1
(en)
|
2011-12-22 |
2018-05-02 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
|
|
EP2802674B1
(en)
|
2012-01-11 |
2020-12-16 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
|
WO2013119602A1
(en)
|
2012-02-06 |
2013-08-15 |
President And Fellows Of Harvard College |
Arrdc1-mediated microvesicles (armms) and uses thereof
|
|
EP3330278A1
(en)
|
2012-02-08 |
2018-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
WO2013138374A2
(en)
|
2012-03-15 |
2013-09-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
WO2013142514A1
(en)
|
2012-03-19 |
2013-09-26 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
|
JP6492003B2
(ja)
|
2012-03-30 |
2019-03-27 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
|
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
|
WO2013151666A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
WO2013154798A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EP3336189A1
(en)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
KR20220028183A
(ko)
|
2012-04-25 |
2022-03-08 |
사노피 |
마이크로rna 화합물 및 mir-21 활성 조절 방법
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
EP3511416A1
(en)
|
2012-05-16 |
2019-07-17 |
Translate Bio MA, Inc. |
Compositions and methods for modulating gene expression
|
|
EP2850186B1
(en)
|
2012-05-16 |
2018-12-19 |
Translate Bio MA, Inc. |
Compositions and methods for modulating smn gene family expression
|
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
US9518261B2
(en)
|
2012-05-22 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of enhancer RNA mediated gene expression
|
|
KR20190084354A
(ko)
|
2012-05-24 |
2019-07-16 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
|
|
US9487780B2
(en)
|
2012-06-01 |
2016-11-08 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
HUE051698T2
(hu)
|
2012-06-25 |
2021-03-29 |
Ionis Pharmaceuticals Inc |
UBE3A-ATS expresszió modulálása
|
|
CA2879066C
(en)
|
2012-07-13 |
2019-08-13 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
|
DK2872485T3
(da)
|
2012-07-13 |
2021-03-08 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
WO2014018930A1
(en)
|
2012-07-27 |
2014-01-30 |
Isis Pharmaceuticals. Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
|
EP2906699A4
(en)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
OLIGOMER COMPOUNDS WITH BICYCLIC NUCLEOSIDES AND USES THEREOF
|
|
US9175291B2
(en)
|
2012-10-11 |
2015-11-03 |
Isis Pharmaceuticals Inc. |
Modulation of androgen receptor expression
|
|
EP4052709A1
(en)
|
2012-10-11 |
2022-09-07 |
Ionis Pharmaceuticals, Inc. |
Methods of treating kennedy's disease
|
|
DK2906256T3
(en)
|
2012-10-12 |
2018-11-19 |
Ionis Pharmaceuticals Inc |
SELECTIVE ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
|
|
US20160138014A1
(en)
|
2012-10-12 |
2016-05-19 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
JP6570447B2
(ja)
|
2012-10-15 |
2019-09-04 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｃ９ｏｒｆ７２発現を調節するための組成物
|
|
WO2014062686A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating c9orf72 expression
|
|
EP2906697A4
(en)
|
2012-10-15 |
2016-06-22 |
Ionis Pharmaceuticals Inc |
METHODS OF MONITORING C9ORF72 EXPRESSION
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
|
PT2920308T
(pt)
|
2012-10-31 |
2019-03-20 |
Ionis Pharmaceuticals Inc |
Tratamento de cancro
|
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
AU2013346767B2
(en)
|
2012-11-15 |
2019-04-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
DK2922955T3
(da)
|
2012-11-26 |
2019-05-13 |
Roche Innovation Ct Copenhagen As |
Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
|
|
WO2014093537A1
(en)
|
2012-12-11 |
2014-06-19 |
Isis Pharmaceuticals, Inc. |
Competitive modulation of micrornas
|
|
US20150337002A1
(en)
*
|
2013-01-15 |
2015-11-26 |
Shionogi & Co., Ltd. |
Nucleoside and nucleotide having sulfonamide structure
|
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
RU2018108405A
(ru)
|
2013-01-30 |
2019-02-26 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты углевода и lna-олигонуклеотида
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
EP2951191B1
(en)
|
2013-01-31 |
2018-10-17 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
|
ES2817050T3
(es)
|
2013-02-04 |
2021-04-06 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido selectivos y usos de los mismos
|
|
ES2680599T3
(es)
|
2013-02-14 |
2018-09-10 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión de apolipoproteína C-III (ApoCIII) en poblaciones deficientes en lipoproteína lipasa (LPLD)
|
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
WO2014143158A1
(en)
|
2013-03-13 |
2014-09-18 |
The Broad Institute, Inc. |
Compositions and methods for labeling of agents
|
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
CN111254145A
(zh)
|
2013-03-14 |
2020-06-09 |
Ionis制药公司 |
用于调节tau表达的组合物和方法
|
|
CN105229150A
(zh)
|
2013-03-14 |
2016-01-06 |
安第斯生物技术股份有限公司 |
用于治疗癌症干细胞的反义寡核苷酸
|
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
|
BR112015022621A2
(pt)
|
2013-03-14 |
2017-10-31 |
Andes Biotechnologies S A |
métodos para detecção e tratamento de mieloma múltiplo
|
|
MX366660B
(es)
|
2013-03-14 |
2019-07-18 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
|
JP6649248B2
(ja)
|
2013-05-01 |
2020-02-19 |
レグルス セラピューティクス インコーポレイテッド |
細胞取り込みの向上のための化合物および方法
|
|
EA034731B1
(ru)
|
2013-05-01 |
2020-03-13 |
Регьюлэс Терапьютикс Инк. |
Соединения на основе микрорнк и способы модулирования активности mir-122
|
|
NZ631552A
(en)
|
2013-05-01 |
2017-02-24 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating hbv expression
|
|
EP2999785B1
(en)
|
2013-05-22 |
2018-04-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 irna compositions and methods of use thereof
|
|
IL293657A
(en)
|
2013-05-22 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Preparations of tmprss6 irna and methods of using them
|
|
BR112015029327A2
(pt)
|
2013-05-24 |
2017-09-19 |
Roche Innovation Ct Copenhagen As |
Moduladores de oligonucleotídeo de linfoma 11a/cll de célula b (bcl11a) e usos dos mesmos
|
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
|
EP3656386A1
(en)
|
2013-06-21 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
|
|
AU2014284152B2
(en)
|
2013-06-21 |
2020-01-23 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
PE20160158A1
(es)
|
2013-06-27 |
2016-03-18 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en pcsk9
|
|
EP3017044B1
(en)
|
2013-07-02 |
2020-02-26 |
Ionis Pharmaceuticals, Inc. |
Modulators of growth hormone receptor
|
|
EP3971287A1
(en)
|
2013-07-11 |
2022-03-23 |
ModernaTX, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
EP3022176B8
(en)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Azacyclic constrained analogs of fty720
|
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ｍａ公司 |
用於調節τ蛋白表現之組合物
|
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
|
RS59991B1
(sr)
|
2013-08-08 |
2020-04-30 |
Scripps Research Inst |
Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US9670492B2
(en)
|
2013-08-28 |
2017-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (PKK) expression
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015034928A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EA035433B1
(ru)
|
2013-09-13 |
2020-06-15 |
Ионис Фармасьютикалз, Инк. |
Модуляторы фактора в комплемента
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
MX2016004230A
(es)
|
2013-10-02 |
2016-10-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
|
SG10201910929QA
(en)
|
2013-10-04 |
2020-01-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
CN105637090B
(zh)
|
2013-10-11 |
2020-10-16 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
WO2015061091A1
(en)
|
2013-10-21 |
2015-04-30 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
US10752940B2
(en)
|
2013-11-08 |
2020-08-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for detecting oligonucleotides
|
|
ES2797679T3
(es)
|
2013-12-02 |
2020-12-03 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido y usos de los mismos
|
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
|
KR102344559B1
(ko)
|
2013-12-12 |
2021-12-31 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
|
|
EP3082840B1
(en)
|
2013-12-20 |
2021-03-24 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
|
HUE052243T2
(hu)
|
2013-12-24 |
2021-04-28 |
Ionis Pharmaceuticals Inc |
Az angiopoietin-szerû 3 expressziójának modulációja
|
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
|
SG10201912897UA
(en)
|
2014-01-16 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral design
|
|
EP3960860A3
(en)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
US10036019B2
(en)
|
2014-03-17 |
2018-07-31 |
Ionis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
HUE055877T2
(hu)
|
2014-03-19 |
2021-12-28 |
Ionis Pharmaceuticals Inc |
Ataxin-2 expresszióját módosító készítmények
|
|
HRP20220798T1
(hr)
|
2014-04-01 |
2022-10-14 |
Biogen Ma Inc. |
Pripravci za modulaciju ekspresije sod-1
|
|
DK3129493T3
(da)
|
2014-04-09 |
2021-09-27 |
Scripps Research Inst |
Import af unaturlige eller modificerede nukleosidtriphosphater ind i celler via nukleinsyre-triphosphat-transportører
|
|
ES2932304T3
(es)
|
2014-04-17 |
2023-01-17 |
Biogen Ma Inc |
Composiciones y métodos para la modulación del empalme de SMN2 en un sujeto
|
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
|
WO2015168172A1
(en)
|
2014-04-28 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
EP3757215A3
(en)
|
2014-05-01 |
2021-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
CN106232804B
(zh)
|
2014-05-01 |
2019-10-25 |
Ionis制药公司 |
用于调节补体因子b表达的组合物和方法
|
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
AU2015252917B2
(en)
|
2014-05-01 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating PKK expression
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アンジオテンシノーゲン（ＡＧＴ）ｉＲＮＡ組成物およびその使用
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
|
USD766120S1
(en)
|
2014-06-09 |
2016-09-13 |
Gambro Lundia Ab |
Status light bar
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
CN106559995A
(zh)
|
2014-08-07 |
2017-04-05 |
莱古路斯治疗法股份有限公司 |
靶向代谢紊乱的微小rna
|
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
WO2016033472A1
(en)
|
2014-08-29 |
2016-03-03 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
SG11201702682PA
(en)
|
2014-10-03 |
2017-04-27 |
Cold Spring Harbor Lab |
Targeted augmentation of nuclear gene output
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
US20170327524A1
(en)
|
2014-10-10 |
2017-11-16 |
Hoffmann-La Roche, Inc. |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
WO2016077540A1
(en)
|
2014-11-12 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of comp
|
|
US10364433B2
(en)
|
2014-11-14 |
2019-07-30 |
The Regents Of The University Of California |
Modulation of AGPAT5 expression
|
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
US10400243B2
(en)
|
2014-11-25 |
2019-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of UBE3A-ATS expression
|
|
AU2015360794B2
(en)
|
2014-12-08 |
2021-07-08 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
|
WO2016096938A1
(en)
|
2014-12-16 |
2016-06-23 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
EP3653712B1
(en)
|
2015-02-04 |
2022-11-30 |
F. Hoffmann-La Roche AG |
Tau antisense oligomers and uses thereof
|
|
CN107636159B
(zh)
|
2015-02-04 |
2022-06-14 |
百时美施贵宝公司 |
选择治疗性分子的方法
|
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
ES2848377T3
(es)
|
2015-02-26 |
2021-08-09 |
Ionis Pharmaceuticals Inc |
Moduladores específicos de alelo de RODOPSINA P23H
|
|
EP3265564B1
(en)
|
2015-03-03 |
2022-01-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating mecp2 expression
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US20180036335A1
(en)
|
2015-03-03 |
2018-02-08 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
|
CA2978100C
(en)
|
2015-04-03 |
2023-10-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating tmprss6 expression
|
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
CA2978103A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
EP3311165B1
(en)
|
2015-06-19 |
2020-12-09 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
KR102640776B1
(ko)
|
2015-07-10 |
2024-02-23 |
아이오니스 파마수티컬즈, 인코포레이티드 |
디아실글리세롤 아실전이효소 2(dgat2) 조절제
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
US20180201937A1
(en)
|
2015-08-04 |
2018-07-19 |
The University Of Chicago |
Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
|
|
DK3341479T3
(da)
|
2015-08-24 |
2020-02-24 |
Roche Innovation Ct Copenhagen As |
LNA-G-Proces
|
|
PE20181131A1
(es)
|
2015-09-02 |
2018-07-17 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
|
|
KR102641298B1
(ko)
|
2015-09-14 |
2024-03-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
|
US20180273577A1
(en)
|
2015-09-24 |
2018-09-27 |
Ionis Pharmaceuticals, Inc. |
Modulators of kras expression
|
|
CN108366990B
(zh)
|
2015-09-24 |
2021-09-03 |
加利福尼亚大学董事会 |
合成的鞘脂类分子、药物、它们的合成方法及治疗方法
|
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
|
MX2018004307A
(es)
|
2015-10-08 |
2018-05-01 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de angiotensinogeno.
|
|
CA3000971A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
WO2017066211A1
(en)
|
2015-10-12 |
2017-04-20 |
Advanced Cell Diagnostics, Inc. |
In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
|
EP3371201A4
(en)
|
2015-11-06 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
BR122023026882A2
(pt)
|
2015-11-06 |
2024-01-23 |
Ionis Pharmaceuticals, Inc |
Uso de um composto oligomérico
|
|
RS61529B9
(sr)
|
2015-11-12 |
2024-04-30 |
Hoffmann La Roche |
Oligonukleotidi za indukovanje ekspresije paternalnog ube3a
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
JP7049248B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
常染色体優性精神遅滞－５とドラベ症候群の処置のためのアンチセンスオリゴマー
|
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
|
WO2017111137A1
(ja)
*
|
2015-12-22 |
2017-06-29 |
味の素株式会社 |
オリゴヌクレオチドの製造方法
|
|
US10907160B2
(en)
|
2016-01-05 |
2021-02-02 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
US11008608B2
(en)
|
2016-02-26 |
2021-05-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplexed single molecule RNA visualization with a two-probe proximity ligation system
|
|
EP3423581A4
(en)
|
2016-03-04 |
2020-03-04 |
Rhode Island Hospital |
TARGETING MIKRORNA FOR CANCER TREATMENT
|
|
US11136577B2
(en)
|
2016-03-09 |
2021-10-05 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for inhibiting PMP22 expression
|
|
JP6748219B2
(ja)
|
2016-03-14 |
2020-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
US11267843B2
(en)
|
2016-03-18 |
2022-03-08 |
Roche Innovation Center Copenhagen A/S |
Stereodefining L-monomers
|
|
WO2017180835A1
(en)
|
2016-04-13 |
2017-10-19 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
KR20190003740A
(ko)
|
2016-05-06 |
2019-01-09 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
|
|
EP3455232B1
(en)
|
2016-05-12 |
2020-05-06 |
Roche Innovation Center Copenhagen A/S |
Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
|
|
JP7080826B2
(ja)
|
2016-05-16 |
2022-06-06 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
|
|
JP6876383B2
(ja)
*
|
2016-06-07 |
2021-05-26 |
富士通オプティカルコンポーネンツ株式会社 |
波長可変光源
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
BR112018075667B1
(pt)
|
2016-06-14 |
2024-02-20 |
Biogen Ma, Inc |
Métodos para separar um oligonucleotídeo alvo de uma mistura contendo o oligonucleotídeo alvo e uma impureza relacionada com o produto
|
|
WO2017219017A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
WO2017216325A1
(en)
|
2016-06-17 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
In vitro nephrotoxicity screening assay
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
JP7049271B2
(ja)
|
2016-06-17 |
2022-04-06 |
エフ．ホフマン－ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
|
ES2929047T3
(es)
|
2016-06-24 |
2022-11-24 |
Scripps Research Inst |
Transportador de nucleósido trifosfato novedoso y usos del mismo
|
|
MX2018015722A
(es)
|
2016-07-01 |
2019-05-27 |
Hoffmann La Roche |
Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
CA3030701A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
|
US11730823B2
(en)
|
2016-10-03 |
2023-08-22 |
President And Fellows Of Harvard College |
Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
|
|
CN109661233A
(zh)
|
2016-10-06 |
2019-04-19 |
Ionis 制药公司 |
缀合低聚化合物的方法
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US20190284621A1
(en)
|
2016-11-11 |
2019-09-19 |
Roche Innovation Center Copenhagen A/S |
Therapeutic oligonucleotides capture and detection
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
CN110177544A
(zh)
|
2016-11-29 |
2019-08-27 |
普尔泰克健康有限公司 |
用于递送治疗剂的外泌体
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
TWI790217B
(zh)
|
2016-12-16 |
2023-01-21 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
|
|
US20190345495A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20190367920A1
(en)
|
2017-01-13 |
2019-12-05 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
EP3568478A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
EP3568477A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3601309A1
(en)
|
2017-03-29 |
2020-02-05 |
Roche Innovation Center Copenhagen A/S |
Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
|
|
CN110913898B
(zh)
|
2017-04-18 |
2024-04-05 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
US11401519B2
(en)
|
2017-06-07 |
2022-08-02 |
University Of Massachusetts |
Anti-ADAM33 oligonucleotides and related methods
|
|
US11814407B2
(en)
|
2017-06-28 |
2023-11-14 |
Roche Innovation Center Copenhagen A/S |
Multiple coupling and oxidation method
|
|
JP7325341B2
(ja)
|
2017-07-11 |
2023-08-14 |
シンソークス，インク． |
非天然ヌクレオチドの組み込み及びその方法
|
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
JP2020529976A
(ja)
|
2017-08-03 |
2020-10-15 |
シンソークス，インク． |
自己免疫疾患の処置のためのサイトカイン抱合体
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
AU2018322319B2
(en)
|
2017-08-25 |
2021-08-05 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
EP3694995A1
(en)
|
2017-10-13 |
2020-08-19 |
Roche Innovation Center Copenhagen A/S |
Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
|
|
AU2018350693B2
(en)
|
2017-10-16 |
2021-03-04 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
|
|
WO2019089922A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
JP2021506239A
(ja)
|
2017-12-14 |
2021-02-22 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
複合アンチセンス化合物及びその使用
|
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
|
MX2020005872A
(es)
|
2017-12-21 |
2020-08-13 |
Hoffmann La Roche |
Diagnostico complementario para antagonistas de acido ribonucleico (arn) de proteina a1 de alto requerimiento de temperatura a (htra1).
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
EP4092117A1
(en)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
KR20200104345A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드
|
|
EP4092118A1
(en)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Novel thiophosphoramidites
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
KR20200140240A
(ko)
|
2018-01-12 |
2020-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
PE20201501A1
(es)
|
2018-01-12 |
2020-12-29 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
|
|
CA3085964A1
(en)
|
2018-01-12 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
RU2020127049A
(ru)
|
2018-01-15 |
2022-02-17 |
Айонис Фармасьютикалс, Инк. |
Модуляторы экспрессии dnm2
|
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
JP2021511029A
(ja)
|
2018-01-18 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
KR20200108315A
(ko)
|
2018-02-09 |
2020-09-17 |
제넨테크, 인크. |
Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드
|
|
AU2019218987A1
(en)
|
2018-02-12 |
2020-07-23 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
JP7500426B2
(ja)
|
2018-02-21 |
2024-06-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用
|
|
SG11202007728QA
(en)
|
2018-02-26 |
2020-09-29 |
Synthorx Inc |
Il-15 conjugates and uses thereof
|
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
|
US11241451B2
(en)
|
2018-03-02 |
2022-02-08 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF4 expression
|
|
CN111868244A
(zh)
|
2018-03-20 |
2020-10-30 |
国立大学法人东京工业大学 |
降低了毒性的反义寡核苷酸
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
MA52661A
(fr)
|
2018-04-05 |
2021-02-17 |
Centre Leon Berard |
Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
|
|
CN112292457A
(zh)
|
2018-04-09 |
2021-01-29 |
领先细胞医疗诊断有限公司 |
用于原位检测核酸的进一步增强信号放大的方法
|
|
AU2019252667A1
(en)
|
2018-04-11 |
2020-10-01 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
|
EP3790991A1
(en)
|
2018-05-07 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
EP3799602A4
(en)
|
2018-05-09 |
2022-02-16 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
|
|
CU20200082A7
(es)
|
2018-05-09 |
2021-06-08 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
WO2019219723A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
|
WO2019233921A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
EP3807411A4
(en)
|
2018-06-14 |
2022-08-03 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR ENHANCING STMN2 EXPRESSION
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
JP7102557B2
(ja)
|
2018-07-03 |
2022-07-19 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｔａｕ発現調節用オリゴヌクレオチド
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
SG11202100348SA
(en)
|
2018-07-13 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotides for modulating rtel1 expression
|
|
WO2020023737A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
AU2019313443A1
(en)
|
2018-07-31 |
2020-11-26 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
AU2019313527A1
(en)
|
2018-07-31 |
2021-02-11 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
SG11202100715WA
(en)
|
2018-08-13 |
2021-02-25 |
Alnylam Pharmaceuticals Inc |
HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
KR20210043634A
(ko)
|
2018-08-15 |
2021-04-21 |
일루미나, 인코포레이티드 |
라이브러리 인리치먼트를 개선하기 위한 조성물 및 방법
|
|
WO2020037125A1
(en)
|
2018-08-16 |
2020-02-20 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020041348A1
(en)
|
2018-08-20 |
2020-02-27 |
Rogcon, Inc. |
Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
EP3841220A1
(en)
|
2018-08-23 |
2021-06-30 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
US20220160870A1
(en)
|
2018-08-28 |
2022-05-26 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
EP3620520A1
(en)
|
2018-09-10 |
2020-03-11 |
Universidad del Pais Vasco |
Novel target to treat a metabolic disease in an individual
|
|
WO2020060986A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
CN112969709A
(zh)
|
2018-11-01 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
靶向tia1的反义寡核苷酸
|
|
MX2021005357A
(es)
*
|
2018-11-08 |
2021-06-30 |
Aligos Therapeutics Inc |
Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
CR20210311A
(es)
|
2018-11-15 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5
|
|
CN113286886A
(zh)
|
2018-11-21 |
2021-08-20 |
Ionis制药公司 |
用于减少朊病毒表达的化合物和方法
|
|
CN113166185A
(zh)
|
2018-11-22 |
2021-07-23 |
罗氏创新中心哥本哈根有限公司 |
作为立体限定的寡核苷酸合成中的活化剂的吡啶鎓盐
|
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
EA202191736A1
(ru)
|
2018-12-20 |
2021-10-01 |
Вир Байотекнолоджи, Инк. |
Комбинированная терапия hbv
|
|
US20220042011A1
(en)
|
2018-12-21 |
2022-02-10 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides targeting card9
|
|
SG11202107669WA
(en)
|
2019-01-16 |
2021-08-30 |
Genzyme Corp |
Serpinc1 irna compositions and methods of use thereof
|
|
WO2020152303A1
(en)
|
2019-01-25 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Lipid vesicle for oral drug delivery
|
|
CN113395971A
(zh)
|
2019-01-31 |
2021-09-14 |
Ionis制药公司 |
Yap1表达的调节剂
|
|
JP2022519271A
(ja)
|
2019-02-06 |
2022-03-22 |
シンソークス， インコーポレイテッド |
Ｉｌ－２コンジュゲートおよびその使用方法
|
|
JP2022520663A
(ja)
|
2019-02-15 |
2022-03-31 |
アドヴァンスド セル ダイアグノスティクス，インコーポレイテッド |
ｉｎ ｓｉｔｕハイブリダイゼーションによって、核酸をマルチプレックス検出する方法
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
JP2022521510A
(ja)
|
2019-02-20 |
2022-04-08 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホノアセテートギャップマー型オリゴヌクレオチド
|
|
WO2020173845A1
(en)
|
2019-02-26 |
2020-09-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide formulation method
|
|
TW202045724A
(zh)
|
2019-02-27 |
2020-12-16 |
美商Ionis製藥公司 |
Malat1表現之調節劑
|
|
US20220184216A1
(en)
|
2019-03-05 |
2022-06-16 |
Hoffmann-La Roche Inc. |
Intracellular targeting of molecules
|
|
MX2021011242A
(es)
|
2019-03-21 |
2022-01-19 |
Codiak Biosciences Inc |
Conjugados de vesícula extracelular y usos de estos.
|
|
EP3941483A4
(en)
|
2019-03-21 |
2023-10-18 |
Arnay Sciences, Llc |
ANTISEN OLIGONUCLEOTIDES FOR ALLEL SPECIFICITY
|
|
CA3135180A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
|
EP3950006A4
(en)
|
2019-03-29 |
2024-06-12 |
Mitsubishi Tanabe Pharma Corp |
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR SETTING DUX4 EXPRESSION
|
|
BR112021019182A2
(pt)
|
2019-04-03 |
2022-05-31 |
Bristol Myers Squibb Co |
Oligonucleotídeos angptl2 antissenso e seus usos
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
EP3947677A1
(en)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
US20220194976A1
(en)
|
2019-04-16 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Nucleotide P(V) Monomers
|
|
EP3962918A1
(en)
|
2019-04-30 |
2022-03-09 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing rhenium chelated mag3 oligonucleotides
|
|
EP3963072A1
(en)
|
2019-05-03 |
2022-03-09 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
EP3966328A4
(en)
|
2019-05-06 |
2023-10-18 |
University Of Massachusetts |
ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
|
|
EP3969588A1
(en)
|
2019-05-13 |
2022-03-23 |
VIR Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
EP3976791A4
(en)
|
2019-05-28 |
2023-10-11 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING FOOT EXPRESSION
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
EP3983543A4
(en)
|
2019-06-14 |
2023-05-03 |
The Scripps Research Institute |
REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS
|
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4013872A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
|
CA3147369A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting cebp/beta
|
|
CA3145924A1
(en)
|
2019-08-14 |
2021-02-18 |
Yi Zhang |
Extracellular vesicle linked to molecules and uses thereof
|
|
JP2022544289A
(ja)
|
2019-08-14 |
2022-10-17 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
|
|
WO2021030769A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with nras antisense oligonucleotides
|
|
US20230132093A1
(en)
|
2019-08-14 |
2023-04-27 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
|
JP2022544587A
(ja)
|
2019-08-15 |
2022-10-19 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
結合修飾オリゴマー化合物及びその使用
|
|
KR20220047598A
(ko)
|
2019-08-15 |
2022-04-18 |
신톡스, 인크. |
Il-2 콘쥬게이트를 사용한 면역 종양학 병용 요법
|
|
JP2022544817A
(ja)
|
2019-08-23 |
2022-10-21 |
シンソークス， インコーポレイテッド |
Ｉｌ－１５コンジュゲートおよびその使用
|
|
JP2022546570A
(ja)
|
2019-09-03 |
2022-11-04 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
|
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
US20230241089A1
(en)
|
2019-09-25 |
2023-08-03 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
WO2021074772A1
(en)
|
2019-10-14 |
2021-04-22 |
Astrazeneca Ab |
Modulators of pnpla3 expression
|
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
MX2022004726A
(es)
|
2019-10-22 |
2022-05-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de componente c3 de complemento y metodos de uso de las mismas.
|
|
AU2020376840A1
(en)
|
2019-11-01 |
2022-04-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CN115175704A
(zh)
|
2019-11-04 |
2022-10-11 |
新索思股份有限公司 |
白介素10缀合物及其用途
|
|
EP4058577A1
(en)
|
2019-11-13 |
2022-09-21 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
CN115151641A
(zh)
|
2019-12-13 |
2022-10-04 |
阿尔尼拉姆医药品有限公司 |
人类染色体9开放阅读框72(C9ORF72)iRNA剂组合物及其使用方法
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
|
|
EP4077668A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of scamp3 inhibitors for treating hepatitis b virus infection
|
|
EP4077670A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
EP4077669A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of sbds inhibitors for treating hepatitis b virus infection
|
|
CN114901821A
(zh)
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
WO2021122993A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of saraf inhibitors for treating hepatitis b virus infection
|
|
CN114829603A
(zh)
|
2019-12-20 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于抑制scn9a表达的增强寡核苷酸
|
|
MX2022007909A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
|
|
MX2022007908A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
TW202140786A
(zh)
|
2020-02-10 |
2021-11-01 |
美商艾爾妮蘭製藥公司 |
用於靜默ｖｅｇｆ－ａ表現之組合物及方法
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
JP2023516142A
(ja)
|
2020-02-28 |
2023-04-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ７３エクソン７スプライシングを調節するためのオリゴヌクレオチド
|
|
CN115279379A
(zh)
|
2020-02-28 |
2022-11-01 |
Ionis 制药公司 |
用于调节smn2的化合物和方法
|
|
TW202146651A
(zh)
|
2020-03-02 |
2021-12-16 |
日商田邊三菱製藥股份有限公司 |
ｍｉＲ－３３ｂ阻礙物質所致之動脈瘤的預防或治療
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021178778A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin (ttr)
|
|
WO2021178736A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
コロナウイルスｉＲＮＡ組成物およびその使用方法
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
EP4133079A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
CN115955972A
(zh)
|
2020-04-27 |
2023-04-11 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白E(APOE)iRNA剂组合物及其使用方法
|
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
|
JP2023524065A
(ja)
|
2020-05-01 |
2023-06-08 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ａｔｘｎ１を調節するための化合物及び方法
|
|
EP4150084A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
JP2023527693A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック， インコーポレイテッド |
神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
|
|
EP4149486A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
|
EP4151237A1
(en)
|
2020-05-12 |
2023-03-22 |
Mitsubishi Tanabe Pharma Corporation |
Compound, method and pharmaceutical composition for regulating expression of ataxin 3
|
|
JP2023526267A
(ja)
|
2020-05-13 |
2023-06-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
プログラニュリン標的オリゴヌクレオチドアゴニスト
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
EP4168546A1
(en)
|
2020-06-18 |
2023-04-26 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
|
AU2021296848A1
(en)
|
2020-06-24 |
2023-02-09 |
Humabs Biomed Sa |
Engineered hepatitis B virus neutralizing antibodies and uses thereof
|
|
IL299074A
(en)
|
2020-06-25 |
2023-02-01 |
Synthorx Inc |
Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
AU2021299290A1
(en)
|
2020-06-29 |
2023-01-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating PLP1
|
|
CN116209478A
(zh)
|
2020-07-17 |
2023-06-02 |
田边三菱制药株式会社 |
肌病的预防或治疗剂
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
|
|
EP4200419A2
(en)
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｇタンパク質共役受容体７５（ＧＰＲ７５）ｉＲＮＡ組成物およびその使用方法
|
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
CA3194880A1
(en)
|
2020-10-09 |
2022-04-14 |
Carolina E. CAFFARO |
Immuno oncology therapies with il-2 conjugates
|
|
MX2023004029A
(es)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
WO2022103999A1
(en)
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CA3202569A1
(en)
|
2020-11-18 |
2022-05-27 |
Lemba Bv |
Umlilo antisense transcription inhibitors
|
|
IL302817A
(en)
|
2020-11-18 |
2023-07-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating angiotensinogen expression
|
|
WO2022106695A1
(en)
|
2020-11-23 |
2022-05-27 |
Alpha Anomeric Sas |
Nucleic acid duplexes
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
AR124227A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
CN116568696A
(zh)
|
2020-12-08 |
2023-08-08 |
豪夫迈·罗氏有限公司 |
二硫代磷酸酯寡核苷酸的新颖合成
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
AR124378A1
(es)
|
2020-12-18 |
2023-03-22 |
Hoffmann La Roche |
Oligonucleótidos antisentido dirigida a progranulina
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
|
EP4291243A1
(en)
|
2021-02-12 |
2023-12-20 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
|
IL304880A
(en)
|
2021-02-12 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
|
|
KR20230146603A
(ko)
|
2021-02-17 |
2023-10-19 |
론자 세일즈 아게 |
최적화 링커와 고정 모이어티를 통해 생물학적 활성 분자에 연결된 세포외 소포체
|
|
WO2022178149A2
(en)
|
2021-02-17 |
2022-08-25 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
EP4298218A1
(en)
|
2021-02-26 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
IL305414A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
JP2024512635A
(ja)
|
2021-03-29 |
2024-03-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
|
|
WO2022213118A1
(en)
|
2021-03-31 |
2022-10-06 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
KR20230166101A
(ko)
|
2021-04-01 |
2023-12-06 |
론자 세일즈 아게 |
세포외 소포 조성물
|
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
|
EP4330392A1
(en)
|
2021-04-26 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
EP4331606A1
(en)
|
2021-04-30 |
2024-03-06 |
Kyoto University |
Prevention or treatment of myopathy using mir-33b inhibitor
|
|
EP4337264A1
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating tissue distribution of intracellular therapeutics
|
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256354A1
(en)
|
2021-05-29 |
2022-12-08 |
1Globe Health Institute Llc |
Short duplex dna as a novel gene silencing technology and use thereof
|
|
AU2022285661A1
(en)
|
2021-05-29 |
2023-12-21 |
1Globe Health Institute Llc |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
WO2022256538A1
(en)
|
2021-06-03 |
2022-12-08 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
|
JP2024521907A
(ja)
|
2021-06-04 |
2024-06-04 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ヒト９番染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物及びその使用方法
|
|
WO2022258555A1
(en)
|
2021-06-08 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
|
CA3223192A1
(en)
|
2021-06-18 |
2022-12-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ifnar1 expression
|
|
EP4359006A1
(en)
|
2021-06-23 |
2024-05-01 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
EP4363580A1
(en)
|
2021-06-30 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
|
|
CA3228255A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
|
EP4384617A1
(en)
|
2021-08-13 |
2024-06-19 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
|
WO2023021046A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
IL311139A
(en)
|
2021-09-01 |
2024-04-01 |
Entrada Therapeutics Inc |
Compounds and methods for skipping exon 44 in Duchenne muscular dystrophy
|
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
AR127158A1
(es)
|
2021-09-29 |
2023-12-27 |
Hoffmann La Roche |
Oligonucléotido antisentido para la edición de arn asociado a enfermedades de poliglutamina
|
|
AU2022356427A1
(en)
|
2021-09-30 |
2024-05-09 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AR127477A1
(es)
|
2021-10-29 |
2024-01-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
|
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
CA3237770A1
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
WO2023086292A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
|
WO2023127857A1
(ja)
*
|
2021-12-27 |
2023-07-06 |
株式会社理研ジェネシス |
新規人工核酸、その製造方法及び用途
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
US20240167040A1
(en)
|
2022-02-21 |
2024-05-23 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotide
|
|
WO2023178144A2
(en)
|
2022-03-16 |
2023-09-21 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
|
TW202409276A
(zh)
|
2022-05-18 |
2024-03-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之靶向ｒｎａ結合蛋白位點的寡核苷酸
|
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024119145A1
(en)
|
2022-12-01 |
2024-06-06 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2024124041A1
(en)
|
2022-12-07 |
2024-06-13 |
Advanced Cell Diagnostics, Inc. |
Multiplexed detection of nucleic acid targets
|